A comparative study of different classification algorithms on RNA-Seq cancer data
Article Sidebar
Main Article Content
Abstract
Gene mutations are the most important reason of cancer diseases, and there are different kind of causing genes across these diseases. RNA-Seq technology enables us to allow for gathering information about many genes simultaneously; hence, RNA-Seq data can be used for cancer diagnosis and classification. In this study, RNA-Seq dataset for renal cell cancer is analysed using three different developed classification methods: random forest (RF), artificial neural network (ANN) and deep learning (DL). The genes in our dataset are related to the following cancer types: kidney renal papillary cell, kidney renal clear cell and kidney chromophore carcinomas. It suggests that the DL method gives the highest accuracy rate compared to RF and ANN for 95.15%, 91.83% and 89.22%, respectively. We believe that the results acquired in this study will make a contribution to the classification of cancer types and support doctors in their processes of decision making.
Keywords: Classification, gene-expression, RNA-Seq, DL.
Downloads
Article Details
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).